<DOC>
	<DOCNO>NCT00320216</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety initial single multiple subcutaneous injection CNTO 1275 treatment patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>A Safety Effectiveness Study CNTO 1275 Patients With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double blind ( neither physician patient know treatment patient receives ) , parallel-group , multicenter study determine effectiveness safety two different dos CNTO 1275 administer subcutaneously one time multiple dos compare placebo patient moderate severe plaque-type psoriasis ( common type psoriasis ) . The dose CNTO 1275 45 90 mg administer subcutaneously four weekly dos . Patients inadequately respond treatment may receive one additional dose . Patients monitor safety throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis least 6 month Plaquetype psoriasis cover least 10 % total body surface area Psoriasis areaandseverity index score 12 great Considered treat dermatologist candidate phototherapy systemic treatment psoriasis Women childbearing potential men must agree use adequate birth control measure Have history latent active tuberculosis Currently nonplaque form psoriasis druginduced psoriasis Women pregnant nursing , men woman plan pregnancy enrol study Patients history chronic recurrent infectious disease serious infection require hospitalization intravenous antibiotic within previous 2 month Patients ever nontuberculous mycobacterial infection opportunistic infection Patients know infected human immunodeficiency virus , hepatitis B , hepatitis C Patients current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease Have know malignancy history malignancy within previous 5 year ( exception basal cell carcinoma skin treat evidence recurrence )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Stelara</keyword>
	<keyword>Interleukin-12</keyword>
	<keyword>IL-12</keyword>
	<keyword>Interleukin-23</keyword>
	<keyword>IL-23</keyword>
</DOC>